Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Extension Study to Assess the Long Term Safety of Treatment With BI 655130 Administered Subcutaneously in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT04086121 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT04086121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04086121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Extension Study to Assess the Long Term Safety of Treatment With BI 655130 Administered Subcutaneously in Adult Patients With Moderate to Severe Atopic Dermatitis
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Terminated
Start date
September 24, 2019
Completion date
February 23, 2022
Enrollment
14 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, atopic